{"id":12057,"date":"2025-02-12T13:41:35","date_gmt":"2025-02-12T08:11:35","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=12057"},"modified":"2025-09-10T17:29:44","modified_gmt":"2025-09-10T11:59:44","slug":"alzheimers-disease-pipeline","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline","title":{"rendered":"Exploring the Current Alzheimer&#8217;s Disease Drug Development Pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e4980222708\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e4980222708\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Current_Landscape_of_Alzheimers_Disease_Drug_Development\" >Current Landscape of Alzheimer&#8217;s Disease Drug Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Key_Targets_in_Alzheimers_Disease_Drug_Development\" >Key Targets in Alzheimer&#8217;s Disease Drug Development<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Amyloid_Beta_A%CE%B2_as_a_Target\" >Amyloid Beta (A\u03b2) as a Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Tau_Protein_as_a_Target\" >Tau Protein as a Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Other_Emerging_Targets_in_AD_Drug_Development\" >Other Emerging Targets in AD Drug Development<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Challenges_in_AD_Drug_Development\" >Challenges in AD Drug Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Recent_Advances_and_Success_Stories\" >Recent Advances and Success Stories<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Breakthroughs_in_Early_Diagnosis\" >Breakthroughs in Early Diagnosis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Expanding_Treatment_Options\" >Expanding Treatment Options<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#New_Targets_and_Emerging_Therapies\" >New Targets and Emerging Therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Repurposed_Alzheimers_Drugs_in_the_Pipeline_Showing_Promise\" >Repurposed Alzheimer\u2019s Drugs in the Pipeline Showing Promise<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Regulatory_Setbacks_and_Challenges\" >Regulatory Setbacks and Challenges<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Path_to_the_Future\" >Path to the Future<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Alzheimer&#8217;s disease<\/strong> continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately <strong>16 million diagnosed prevalent<\/strong> <strong>cases in 2023.<\/strong> This rising <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">AD prevalence highlights<\/a> an urgent need for innovative treatments to mitigate the growing disease burden on both patients and caregivers. The aging global population, coupled with the increasing Alzheimer&#8217;s disease diagnosis rate, makes it a critical focus for the pharmaceutical industry, driving robust research and development efforts.&nbsp;<\/p>\n\n\n\n<p>In the United States, the disease disproportionately affects females, with<strong> 4.6 million women<\/strong> diagnosed in <strong>2023<\/strong> compared to <strong>2.3 million men.<\/strong> This gender disparity is expected to widen by 2034, as Alzheimer\u2019s becomes an even greater public health concern. DelveInsight\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer\u2019s disease epidemiology-based market report<\/a> projects a continued rise in the overall diagnosed prevalent cases of Alzheimer\u2019s disease in the coming years, reflecting an urgent need for effective therapeutic solutions.<\/p>\n\n\n\n<p>The need for novel, disease-modifying therapies has never been more pressing, and this demand is driving the exploration of cutting-edge treatments, from amyloid-targeting agents to more comprehensive neuroprotective approaches.<\/p>\n\n\n\n<p>With a dynamic and evolving drug pipeline, pharmaceutical companies are increasingly focused on developing therapies that slow the disease\u2019s progression and improve patient quality of life. As we look to the future, new drug development, advanced biomarkers, and clinical trial strategies are expected to play pivotal roles in transforming the Alzheimer&#8217;s disease landscape, offering hope to millions affected worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-landscape-of-alzheimer-s-disease-drug-development\"><span class=\"ez-toc-section\" id=\"Current_Landscape_of_Alzheimers_Disease_Drug_Development\"><\/span>Current Landscape of Alzheimer&#8217;s Disease Drug Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current landscape of <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\">Alzheimer&#8217;s disease drug development<\/a> is characterized by a combination of approved therapies and ongoing research into new treatment options. In 2023, the AD market in the 7MM was valued at approximately <strong>USD 3.6 billion,<\/strong> with a range of therapies contributing to this figure. The approved treatments primarily focus on managing symptoms rather than addressing the underlying disease pathology. These include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which help improve cognitive function in the short term, and memantine, an NMDA receptor antagonist, which aids in preventing excess glutamate activity in the brain.<\/p>\n\n\n\n<p>Despite these treatment options, none of the current therapies can halt the progression of Alzheimer&#8217;s disease or reverse its underlying pathology. The focus remains on symptom management, with patients often relying on these medications to temporarily slow cognitive decline.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"236\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png\" alt=\"Alzheimer's-Disease-Market-Insights-(2023)\" class=\"wp-image-31026\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-300x69.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-150x35.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-768x177.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1536x353.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-2048x471.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Recent advancements in the field have introduced the use of anti-amyloid monoclonal antibodies, such as <strong>LEQEMBI<\/strong> (lecanemab), which targets amyloid plaques in the brain. The hope is that these therapies can slow the cognitive decline associated with Alzheimer&#8217;s by reducing the accumulation of amyloid-beta proteins. However, these new treatments have faced regulatory and clinical scrutiny concerning their efficacy and safety, particularly regarding their ability to significantly alter disease progression.<\/p>\n\n\n\n<p>The treatment landscape also incorporates non-pharmacological interventions, which play a crucial role in supporting patients&#8217; overall well-being. Cognitive therapies, physical exercise, and lifestyle modifications are vital components of care that contribute to the mental and physical health of Alzheimer\u2019s patients.<\/p>\n\n\n\n<p>Looking ahead, the AD drug development pipeline remains dynamic, with several emerging therapies poised to enter the market in the coming years. These novel treatments, along with ongoing research into disease-modifying drugs, are expected to reshape the Alzheimer\u2019s treatment landscape, offering patients and their families hope for more effective management and potentially disease-modifying therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-targets-in-alzheimer-s-disease-drug-development\"><span class=\"ez-toc-section\" id=\"Key_Targets_in_Alzheimers_Disease_Drug_Development\"><\/span>Key Targets in Alzheimer&#8217;s Disease Drug Development<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Alzheimer\u2019s disease drug development focuses on multiple biological targets, aiming to slow disease progression and alleviate symptoms. The primary targets include <strong>amyloid beta (A\u03b2) plaques<\/strong> and <strong>tau proteins<\/strong>, which are hallmark pathological features of AD. Additionally, researchers are exploring other mechanisms, such as neurotransmitter modulation, inflammation, and oxidative stres,s to develop more effective therapies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-amyloid-beta-a\u03b2-as-a-target\"><span class=\"ez-toc-section\" id=\"Amyloid_Beta_A%CE%B2_as_a_Target\"><\/span><strong>Amyloid Beta (A\u03b2) as a Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>A\u03b2 accumulation in the brain is a central feature of AD pathology, leading to plaque formation and neuronal toxicity. Targeting A\u03b2 aims to reduce or clear these plaques to slow cognitive decline.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aducanumab (Aduhelm\u00ae)<\/strong> \u2013 FDA-approved for early AD with mild cognitive impairment (MCI), targeting aggregated A\u03b2 to reduce plaque buildup.<\/li>\n\n\n\n<li><strong>Lecanemab (Leqembi\u00ae)<\/strong> \u2013 FDA-approved for early AD, shown to reduce amyloid plaques and slow disease progression.<\/li>\n\n\n\n<li><strong>Donanemab<\/strong> \u2013 Recently FDA-approved for early AD, focusing on clearing existing amyloid plaques to slow cognitive decline.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-tau-protein-as-a-target\"><span class=\"ez-toc-section\" id=\"Tau_Protein_as_a_Target\"><\/span><strong>Tau Protein as a Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Tau proteins form <strong>neurofibrillary tangles (NFTs)<\/strong> in AD, disrupting neuronal function. Targeting tau aggregation may help prevent neurodegeneration.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tau aggregation inhibitors<\/strong> \u2013 Designed to prevent or disrupt the formation of toxic tau oligomers and NFTs.<\/li>\n\n\n\n<li><strong>Anti-tau monoclonal antibodies<\/strong> \u2013 Aiming to reduce tau pathology and slow disease progression.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-other-emerging-targets-in-ad-drug-development\"><span class=\"ez-toc-section\" id=\"Other_Emerging_Targets_in_AD_Drug_Development\"><\/span><strong>Other Emerging Targets in AD Drug Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Beyond amyloid and tau, researchers are exploring additional pathways involved in AD progression:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Apolipoprotein E (ApoE)<\/strong> \u2013 A genetic risk factor influencing amyloid deposition and cholesterol metabolism in the brain.<\/li>\n\n\n\n<li><strong>Neurotransmitter receptors<\/strong> \u2013 Drugs targeting cholinergic and glutamatergic systems aim to improve cognitive function and neuronal communication.<\/li>\n\n\n\n<li><strong>Inflammation<\/strong> \u2013 Chronic neuroinflammation contributes to AD progression, making anti-inflammatory strategies a promising avenue.<\/li>\n\n\n\n<li><strong>Synaptic function<\/strong> \u2013 Enhancing synaptic plasticity and neuroprotection may help preserve cognitive abilities.<\/li>\n\n\n\n<li><strong>Oxidative stress<\/strong> \u2013 Addressing free radical damage and mitochondrial dysfunction could mitigate neuronal loss.<\/li>\n\n\n\n<li><strong>Cholinergic deficits<\/strong> \u2013 Acetylcholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, help boost acetylcholine levels to temporarily improve cognitive function.<\/li>\n<\/ul>\n\n\n\n<p>As research evolves, multi-targeted approaches integrating amyloid clearance, tau modulation, and neuroprotection are expected to play a crucial role in the next generation of AD therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-challenges-in-ad-drug-development\"><span class=\"ez-toc-section\" id=\"Challenges_in_AD_Drug_Development\"><\/span>Challenges in AD Drug Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alzheimer\u2019s disease drug development is a formidable challenge, marked by <strong>high failure rates, complex disease mechanisms, and the lack of disease-modifying treatments<\/strong>. Despite years of research, most therapies have focused on symptom management rather than stopping or reversing neurodegeneration.<\/p>\n\n\n\n<p>One of the biggest hurdles is <strong>the multifactorial nature of AD<\/strong>, involving <strong>amyloid plaques, tau tangles, neuroinflammation, and synaptic dysfunction<\/strong>. Many therapies have targeted amyloid beta, but mixed clinical outcomes suggest a need for <strong>multi-targeted approaches<\/strong>. Additionally, the <strong>slow progression of the disease makes clinical trials lengthy and costly<\/strong>, while the lack of <strong>clear biomarkers<\/strong> complicates early diagnosis and treatment efficacy assessments.<\/p>\n\n\n\n<p>Even with recent FDA-approved therapies like <strong>aducanumab and lecanemab<\/strong>, concerns around <strong>safety, effectiveness, and accessibility<\/strong> remain. Moving forward, success in AD drug development will require <strong>combination therapies, early detection strategies, and innovative clinical trial designs<\/strong> to change the trajectory of this devastating disease finally.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-recent-advances-and-success-stories\"><span class=\"ez-toc-section\" id=\"Recent_Advances_and_Success_Stories\"><\/span>Recent Advances and Success Stories<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The field of Alzheimer\u2019s disease research has witnessed <strong>remarkable advancements in recent years<\/strong>, with breakthroughs in diagnostics, novel drug approvals, and promising clinical trial results. These developments reshape the treatment landscape and provide new hope for patients and caregivers.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-breakthroughs-in-early-diagnosis\"><span class=\"ez-toc-section\" id=\"Breakthroughs_in_Early_Diagnosis\"><\/span><strong>Breakthroughs in Early Diagnosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Early detection of Alzheimer\u2019s is crucial in improving patient outcomes, and <strong>Spear Bio Inc.\u2019s<\/strong> recent innovation in blood-based diagnostics marks a significant leap forward. In <strong>January 2025<\/strong>, its <strong>pTau 217 blood test<\/strong> received <strong>Breakthrough Device Designation<\/strong> from the FDA, recognizing its potential to address the <strong>critical unmet need for early and accurate AD diagnosis<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-expanding-treatment-options\"><span class=\"ez-toc-section\" id=\"Expanding_Treatment_Options\"><\/span><strong>Expanding Treatment Options<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>The <strong>anti-amyloid therapy landscape continues to evolve<\/strong>, with <strong>BioArctic AB and Eisai<\/strong> achieving a key regulatory milestone in <strong>January 2025<\/strong>. The FDA accepted a <strong>Biologics License Application (BLA)<\/strong> for the <strong>Leqembi subcutaneous autoinjector (SC-AI)<\/strong>, a more convenient <strong>weekly maintenance dosing option<\/strong> for patients with early Alzheimer\u2019s. This innovation aims to enhance patient adherence and accessibility.<\/p>\n\n\n\n<p>Similarly, <strong>Eli Lilly\u2019s Kisunla (donanemab)<\/strong> is making strides on the global stage. In <strong>December 2024<\/strong>, it secured <strong>regulatory approval in China<\/strong>, opening doors for expanded patient access in the <strong>world\u2019s second-largest pharmaceutical market<\/strong>. Following this, in <strong>September 2024<\/strong>, Kisunla also received approval in <strong>Japan<\/strong>, solidifying its presence in major international markets.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-new-targets-and-emerging-therapies\"><span class=\"ez-toc-section\" id=\"New_Targets_and_Emerging_Therapies\"><\/span><strong>New Targets and Emerging Therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>While amyloid beta remains a central target, <strong>phosphorylated tau-directed therapies<\/strong> are also gaining traction. In <strong>January 2025<\/strong>, the FDA granted <strong>Fast Track designation<\/strong> to <strong>posdinemab<\/strong>, a <strong>monoclonal antibody<\/strong> under investigation in the <strong>Phase 2b AuTonomy study<\/strong> for early Alzheimer\u2019s treatment.<\/p>\n\n\n\n<p>At the same time, <strong>Axsome Therapeutics<\/strong> is advancing <strong>AXS-05<\/strong>, a combination of <strong>dextromethorphan and bupropion<\/strong>, for <strong>Alzheimer\u2019s agitation<\/strong>. Despite <strong>mixed late-phase results<\/strong>, the company remains committed to pursuing <strong>FDA approval<\/strong>, recognizing the <strong>urgent need for better symptom management therapies<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-repurposed-alzheimer-s-drugs-in-the-pipeline-showing-promise\"><span class=\"ez-toc-section\" id=\"Repurposed_Alzheimers_Drugs_in_the_Pipeline_Showing_Promise\"><\/span><strong>Repurposed Alzheimer\u2019s Drugs in the Pipeline Showing Promise<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>An unexpected breakthrough emerged from <strong>real-world studies on semaglutide<\/strong>, a <strong>diabetes drug from Novo Nordisk<\/strong>. In <strong>October 2024<\/strong>, a study published in <em>Alzheimer\u2019s and Dementia<\/em> revealed that semaglutide was associated with a <strong>40% to 70% reduction in the risk of AD diagnosis<\/strong> in patients with type 2 diabetes. This follows previous studies linking semaglutide to <strong>lower dementia risk<\/strong>, reinforcing its potential for <strong>future clinical development in Alzheimer\u2019s treatment<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-regulatory-setbacks-and-challenges\"><span class=\"ez-toc-section\" id=\"Regulatory_Setbacks_and_Challenges\"><\/span><strong>Regulatory Setbacks and Challenges<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Despite these advancements, <strong>cost and accessibility remain key hurdles<\/strong>. In <strong>October 2024<\/strong>, <strong>Eli Lilly\u2019s Kisunla<\/strong> faced a setback in the UK, where it was <strong>deemed too expensive for widespread use<\/strong> by regulatory authorities, despite its approval by the <strong>Medicines and Healthcare products Regulatory Agency (MHRA)<\/strong>. This highlights the <strong>ongoing challenge of balancing innovation with affordability<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-path-to-the-future\"><span class=\"ez-toc-section\" id=\"Path_to_the_Future\"><\/span><strong>Path to the Future<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>With these <strong>groundbreaking developments<\/strong> in <strong>diagnostics, drug approvals, and emerging therapies<\/strong>, the Alzheimer\u2019s landscape is evolving faster than ever before. While challenges remain, the industry is making significant strides toward <strong>early detection, better treatment options, and ultimately, a future where Alzheimer\u2019s can be managed more effectively\u2014<em>or even cured<\/em><\/strong><em>.<\/em><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"218\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1024x218.png\" alt=\"Key-Players-Working-in-the-Alzheimer's-Disease-Treatment-Market\" class=\"wp-image-31027\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1024x218.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-300x64.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-150x32.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-768x163.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-1536x326.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133448\/Key-Players-Working-in-the-Alzheimers-Disease-Treatment-Market-2048x435.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s disease pipeline<\/strong><\/a> is undergoing a <strong><em>transformational shift<\/em><\/strong> driven by cutting-edge research, groundbreaking diagnostics, and an expanding arsenal of <strong>Alzheimer\u2019s disease therapies<\/strong>. From next-generation anti-amyloid treatments to novel tau-targeting and neuroprotective strategies, the Alzheimer\u2019s disease therapeutic landscape is more dynamic than ever before. However, the road ahead is not without obstacles\u2014<strong>high drug development failure rates, regulatory scrutiny, and cost barriers<\/strong> continue to challenge progress. Yet, the momentum is undeniable. With emerging biomarkers enabling earlier diagnosis, innovative clinical trial designs accelerating drug approval, and multi-targeted approaches unlocking new possibilities, the future of Alzheimer\u2019s treatment is filled with renewed hope. As science pushes the boundaries, we move closer to a world where <strong>Alzheimer\u2019s is no longer a devastating inevitability but a condition that can be effectively treated\u2014or even prevented.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-31013\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>FAQs<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757505458430\"><strong class=\"schema-faq-question\"><strong>How is the Alzheimer\u2019s patient pool projected to change by 2034?<\/strong><\/strong> <p class=\"schema-faq-answer\">In 2023, there were about 16 million diagnosed cases of Alzheimer\u2019s across the 7MM, and this number is expected to rise sharply by 2034. Women already make up the majority of cases, and the gender gap is projected to widen due to longer female life expectancy and higher susceptibility.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505459901\"><strong class=\"schema-faq-question\"><strong>What was the Alzheimer\u2019s disease market size in 2023, and how is it expected to evolve?<\/strong><\/strong> <p class=\"schema-faq-answer\">The Alzheimer\u2019s market was valued at USD 3.6 billion in 2023, with revenues mostly from symptomatic drugs. With the arrival of anti-amyloid therapies like LEQEMBI and KISUNLA, the market is entering a growth phase, driven by demand for disease-modifying treatments.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505461019\"><strong class=\"schema-faq-question\"><strong>Which therapies are transforming the treatment landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">Anti-amyloid monoclonal antibodies such as Aduhelm, Leqembi, and Kisunla are shifting treatment from symptom relief toward slowing disease progression. While safety and cost remain challenges, these drugs represent the first real step toward modifying the course of Alzheimer\u2019s.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505461525\"><strong class=\"schema-faq-question\"><strong>What role do new diagnostics play in advancing Alzheimer\u2019s care?<\/strong><\/strong> <p class=\"schema-faq-answer\">Early detection is vital, and blood-based biomarkers like Spear Bio\u2019s pTau 217 test, granted FDA Breakthrough Device status in January 2025, are game-changers. These tests are more accessible than PET scans and could allow treatment to begin earlier in the disease course.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505462204\"><strong class=\"schema-faq-question\"><strong>Which pipeline candidates are showing the most promise?<\/strong><\/strong> <p class=\"schema-faq-answer\">Promising late-stage candidates include posdinemab, an anti-tau antibody given FDA Fast Track status in January 2025, and the Leqembi autoinjector under FDA review. Other therapies target inflammation, synaptic health, and neuroprotection, signaling a broader, multi-targeted future.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505463459\"><strong class=\"schema-faq-question\"><strong>Are repurposed drugs making an impact in Alzheimer\u2019s research?<\/strong><\/strong> <p class=\"schema-faq-answer\">Yes, semaglutide, a diabetes drug, showed a 40\u201370% reduction in Alzheimer\u2019s risk in type 2 diabetes patients, according to an October 2024 study. If proven in trials, such repurposed drugs could accelerate access to affordable new treatment options.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757505566420\"><strong class=\"schema-faq-question\"><strong>What challenges continue to hinder Alzheimer\u2019s drug development?<\/strong><\/strong> <p class=\"schema-faq-answer\">Alzheimer\u2019s trials are long, costly, and often end in failure due to the disease\u2019s complexity. Even approved drugs face barriers such as high costs, safety risks, and regulatory pushback, underscoring the need for biomarkers and combination therapies.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer&#8217;s disease continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately 16 million diagnosed prevalent cases in 2023. This rising AD prevalence highlights an urgent need for innovative treatments to mitigate the growing disease burden on both patients and caregivers. The aging global population, coupled with the increasing Alzheimer&#8217;s [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31028,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":3,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2998,7145,6642,6641,72,204,704,418],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-12057","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aducanumab","tag-alzheimers-disease-market","tag-alzheimers-disease-pipeline","tag-alzheimers-disease-therapies","tag-alzheimers-disease","tag-delveinsight","tag-fda","tag-neurodegenerative-disorders","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alzheimer&#039;s Disease pipeline | Alzheimer&#039;s Disease Key companies<\/title>\n<meta name=\"description\" content=\"Key players advancing Alzeimer&#039;s disease pipeline are Eisai, BioArctic AB, Biogen, Hoffmann-La Roche\/Chugai, Anavex Life Sciences, AbbVie...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer&#039;s Disease pipeline | Alzheimer&#039;s Disease Key companies\" \/>\n<meta property=\"og:description\" content=\"Key players advancing Alzeimer&#039;s disease pipeline are Eisai, BioArctic AB, Biogen, Hoffmann-La Roche\/Chugai, Anavex Life Sciences, AbbVie...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T08:11:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T11:59:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzheimer's Disease pipeline | Alzheimer's Disease Key companies","description":"Key players advancing Alzeimer's disease pipeline are Eisai, BioArctic AB, Biogen, Hoffmann-La Roche\/Chugai, Anavex Life Sciences, AbbVie...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline","og_locale":"en_US","og_type":"article","og_title":"Alzheimer's Disease pipeline | Alzheimer's Disease Key companies","og_description":"Key players advancing Alzeimer's disease pipeline are Eisai, BioArctic AB, Biogen, Hoffmann-La Roche\/Chugai, Anavex Life Sciences, AbbVie...","og_url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-12T08:11:35+00:00","article_modified_time":"2025-09-10T11:59:44+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline","url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline","name":"Alzheimer's Disease pipeline | Alzheimer's Disease Key companies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4.png","datePublished":"2025-02-12T08:11:35+00:00","dateModified":"2025-09-10T11:59:44+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Key players advancing Alzeimer's disease pipeline are Eisai, BioArctic AB, Biogen, Hoffmann-La Roche\/Chugai, Anavex Life Sciences, AbbVie...","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505458430"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505459901"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461019"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461525"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505462204"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505463459"},{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505566420"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4.png","width":466,"height":284,"caption":"Exploring the Current Alzheimer's Disease Drug Development Pipeline"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505458430","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505458430","name":"How is the Alzheimer\u2019s patient pool projected to change by 2034?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"In 2023, there were about 16 million diagnosed cases of Alzheimer\u2019s across the 7MM, and this number is expected to rise sharply by 2034. Women already make up the majority of cases, and the gender gap is projected to widen due to longer female life expectancy and higher susceptibility.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505459901","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505459901","name":"What was the Alzheimer\u2019s disease market size in 2023, and how is it expected to evolve?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The Alzheimer\u2019s market was valued at USD 3.6 billion in 2023, with revenues mostly from symptomatic drugs. With the arrival of anti-amyloid therapies like LEQEMBI and KISUNLA, the market is entering a growth phase, driven by demand for disease-modifying treatments.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461019","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461019","name":"Which therapies are transforming the treatment landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Anti-amyloid monoclonal antibodies such as Aduhelm, Leqembi, and Kisunla are shifting treatment from symptom relief toward slowing disease progression. While safety and cost remain challenges, these drugs represent the first real step toward modifying the course of Alzheimer\u2019s.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461525","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505461525","name":"What role do new diagnostics play in advancing Alzheimer\u2019s care?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Early detection is vital, and blood-based biomarkers like Spear Bio\u2019s pTau 217 test, granted FDA Breakthrough Device status in January 2025, are game-changers. These tests are more accessible than PET scans and could allow treatment to begin earlier in the disease course.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505462204","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505462204","name":"Which pipeline candidates are showing the most promise?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Promising late-stage candidates include posdinemab, an anti-tau antibody given FDA Fast Track status in January 2025, and the Leqembi autoinjector under FDA review. Other therapies target inflammation, synaptic health, and neuroprotection, signaling a broader, multi-targeted future.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505463459","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505463459","name":"Are repurposed drugs making an impact in Alzheimer\u2019s research?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Yes, semaglutide, a diabetes drug, showed a 40\u201370% reduction in Alzheimer\u2019s risk in type 2 diabetes patients, according to an October 2024 study. If proven in trials, such repurposed drugs could accelerate access to affordable new treatment options.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505566420","position":7,"url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-pipeline#faq-question-1757505566420","name":"What challenges continue to hinder Alzheimer\u2019s drug development?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Alzheimer\u2019s trials are long, costly, and often end in failure due to the disease\u2019s complexity. Even approved drugs face barriers such as high costs, safety risks, and regulatory pushback, underscoring the need for biomarkers and combination therapies.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133727\/Alzheimers-disease-f4-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Aducanumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Neurodegenerative disorders<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Aducanumab<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease therapies<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Neurodegenerative disorders<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 7 months ago"},"absolute_dates":{"created":"Posted on Feb 12, 2025","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Feb 12, 2025 1:41 pm","modified":"Updated on Sep 10, 2025 5:29 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=12057"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12057\/revisions"}],"predecessor-version":[{"id":33331,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/12057\/revisions\/33331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31028"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=12057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=12057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=12057"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=12057"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=12057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}